Amid recent pressure on the US dollar's credit profile and increased allocation momentum for Hong Kong-listed equities, Hong Kong's pharmaceutical sector has demonstrated a notable new-high effect across the board. Smart Finance APP observed that after the Hang Seng Healthcare Index fell 6.66% in June, it posted back-to-back gains in July and August, accumulating a rise of approximately 24.80% over the two-month period. The underlying logic driving this rally is the dual resonance between rising R&D demand for innovative drugs at home and abroad and the recovery of the CXO sector.

As a leader in the Hong Kong CXO segment, Wuxi Bio (02269) rebounded ahead of the index during this market move, recording three consecutive monthly gains. From June to August, its share price rose approximately 45%, bringing year-to-date gains to over 60%, significantly outperforming both the Hang Seng Index and the broader pharmaceutical sector during the same period. Notably, major investment banks including UBS, CLSA, Goldman Sachs, Nomura, and Daiwa published research reports early this year on Wuxi Bio with target prices in the HK$40 range. However, Wuxi Bio's share price had already broken through the HK$50 mark by late August, surpassing those broker expectations.

As Wuxi Bio's share price surged, international investment banks have recently raised their valuation anchors for the company, with target prices gradually moving up to around HK$50. For instance, UBS raised its target price to HK$51.10 on July 2 with a "Buy" rating; Nomura lifted its target to HK$51.38 in late July with a "Buy" rating; and Morgan Stanley had already increased its target to HK$50 with an "Overweight" rating as early as February this year. During this leading rally, Wuxi Bio has shown a clear upward trajectory with sustained momentum, even breaking through the latest broker targets, reflecting the market's reassessment of the company's fundamentals and long-term growth prospects.

In Smart Finance APP's view, the reason market capital has managed to "outperform" institutional benchmarks lies in the fact that while off-market research remains anchored to historical volatility, stage-specific pressures, and market debates, on-market investors have already priced in a repricing of the global innovative drug supply chain, upstream delivery certainty, and the scarcity value of Wuxi Bio's platform, which has been reflected in the secondary market ahead of time.

Wuxi Bio's 2026 interim results released a strong signal: the project pipeline is accelerating its transition toward later-stage and commercialization phases, while complex molecule businesses further elevate growth quality. The company is moving from project volume expansion toward the concentrated realization of high-value projects, with its long-term valuation logic shifting from R&D-stage reserves to visible growth in commercialization revenue.

Accelerated Manufacturing Growth Once Again Validates Long-Term Investment Thesis

Several major international banks hold highly consistent bullish views on Wuxi Bio, as Goldman Sachs highlighted in its report the three core logic points for overweighting the stock: hard evidence from earnings, technical barriers in complex molecules, and the structural demand for global CXO outsourcing. This 2026 interim report once again validates Wuxi Bio's long-term investment thesis with high-quality data: the accelerated conversion from research (R) to development (D) to manufacturing (M) is becoming a key driver of sustained high growth, and the company's "golden funnel" is entering a full realization phase.

According to the financial report, the company achieved total revenue of RMB 11.8 billion during the period, up approximately 18.4% year-over-year (up 23.4% in USD terms). Adjusted gross profit increased 25.6% year-over-year to RMB 5.7 billion, with adjusted gross margin up 2.8 percentage points to 48.4%. Adjusted net profit and adjusted net profit attributable to shareholders reached RMB 3.9 billion and RMB 3.3 billion respectively, corresponding to year-over-year growth of 38.6% and 38.4%. Despite strong revenue growth, profit growth has significantly outpaced revenue growth, indicating upgrades in operational efficiency, capacity utilization, and business structure, further confirming that the company's core business has entered a higher-quality growth phase.

Wuxi Bio also raised its full-year guidance this time, now expecting revenue growth of 20-23% year-over-year at constant exchange rates (previously 16-20%), and 15-18% at reported rates (previously 13-17%). However, the most critical highlight of this report is not the significant profit elasticity demonstrated by Wuxi Bio, but rather the early manifestation of an accelerated growth trajectory in its core business segment, providing clear investment certainty to the market.

On the business side, Wuxi Bio added 169 comprehensive projects in the first half of 2026. Among these, 123 were new internally generated comprehensive projects, setting a new record with 43% year-over-year growth. Following the consolidation of Wuxi XDC (02268) and the acquisition of Dongyao Pharmaceutical, the company gained 46 additional comprehensive projects. The total number of comprehensive projects has now reached 1,064, with over 70% of new projects and over 50% of total projects being complex molecules such as bispecific/multispecific antibodies and ADCs. This indicates that while Wuxi Bio's project pipeline is expanding, it is also accelerating its upgrade toward higher technical barriers and higher value density.

However, for investors, it is essential not only to recognize the achievement of reaching "1,000 molecules" but also to clearly see through the financial report the structural explosion of Wuxi Bio's CRDMO "golden funnel." Specifically, within the integrated CRDMO platform, preclinical projects reached 525, up 22.4% year-over-year. The R-end business, serving as the traffic entry point of the "golden funnel," is accelerating its expansion, providing the company with quality project screening and delivery for later stages while also enhancing the visibility of mid-to-long-term high-margin revenue growth.

While the R-end accelerates its expansion, the D-end early-stage (Phase I and II) clinical projects reached 433 (303 Phase I and 130 Phase II), up 25.9% year-over-year. The M-end later-stage (Phase III) clinical and commercial manufacturing projects increased to 106 (78 Phase III and 28 commercial manufacturing), up 16.5% year-over-year. These D-end and M-end figures clearly demonstrate the traffic migration and structural optimization within the "golden funnel": a large number of "follow-the-molecule" projects are continuously flowing through the R-D-M chain toward later clinical stages, process validation, and commercialization.

Additionally, in the first half of the year, Wuxi Bio obtained 16 external "win-the-molecule" projects, including 5 later-stage and commercial projects, 2 of which are biosimilar projects. The next-generation site-specific integration cell line platform WuXia™ TrueSite combines development efficiency with production efficiency advantages, significantly shortening project timelines and reducing production costs, making it particularly well-suited for biosimilar market demand. As a result, the growth prospects for Wuxi Bio's M-end future manufacturing business are increasingly clear: first, "follow-the-molecule" projects are steadily advancing toward commercialization; second, "win-the-molecule" projects continue to replenish later-stage and commercial manufacturing pipelines; third, global blockbuster biologics are densely entering patent expiration windows, accelerating biosimilar demand release; and fourth, integrated biologics capabilities further enhance project value. Multiple drivers combined provide support for sustained growth in the manufacturing business.

PPQ (Process Performance Qualification) is a critical verification step before commercial biologics production and serves as a core leading indicator for observing the M-end business. Building on the 28 PPQs completed in 2025, Wuxi Bio has scheduled 34 and 30 PPQs for 2026 and 2027 respectively. The continuously increasing PPQ schedule indicates that more projects are advancing toward commercialization, locking in commercial revenue for the next 1-3 years in advance, making it the most certain leading indicator of performance. In 2026, each of Wuxi Bio's top 3 manufacturing projects is expected to contribute over US$100 million in revenue. The M-end is projected to achieve a compound annual growth rate of 30% over the next three years.

The strong M-end performance is also cross-validated by the company's active capacity expansion. Smart Finance APP understands that this year, Wuxi Bio has been accelerating the construction of its US and Singapore bases on one hand, while rapidly expanding capacity through controlling interest in Dongyao Pharmaceutical and acquiring CDMO assets from Transcenta on the other. To date this year, Wuxi Bio's Ireland base has signed 3 new large-scale commercial manufacturing projects and initiated technology transfers. The MFG8 drug substance manufacturing facility at Wuxi Bio's Hebei base has passed the US FDA pre-approval inspection, further strengthening the delivery foundation for related commercial projects. With reliable quality systems and further expansion expectations, the company has already secured the value release from the M-end. As the global commercial manufacturing capacity foundation is established, the weight of Wuxi Bio's M-end business is rapidly rising, ultimately reflected in subsequent financial results and further validating the company's long-term investment thesis.

Complex Molecule Projects Have Become a "Value Amplifier"

In recent years, Wuxi Bio has achieved precise positioning in high-potential complex molecule areas such as bispecific/multispecific antibodies and ADCs. In the first half of the year, 71% of Wuxi Bio's newly signed projects were bispecific/multispecific antibodies and ADCs, which have not only become the company's "fastest-growing and most profitable" engine but also a key amplifier of its value growth.

At the market level, bispecific/multispecific antibodies and ADCs are experiencing explosive growth. According to PharmaMagic data, global bispecific antibody product sales reached approximately US$16 billion in 2025, up about 27% year-over-year, with approximately 1,800 bispecific therapies currently in development globally. Meanwhile, IQVIA data shows that global ADC product sales reached US$18.8 billion, projected to reach US$36 billion by 2030. The continued volume growth of leading products not only signals that next-generation biologics represented by bispecific/multispecific antibodies and ADCs are becoming the most active innovation tracks globally, but also indicates that the outsourcing penetration rate for bispecific/multispecific antibodies will rapidly increase alongside industry demand.

Although complex molecules present high process barriers, difficult technology transfers, and challenging PPQ validation, Wuxi Bio's platform capabilities in bispecific/multispecific antibodies and ADCs continue to be validated by clients, thanks to its years of complex molecule project experience, quality systems verified by global regulators, and advanced process platforms. Taking bispecific/multispecific antibodies as an example, the interim report shows that the integrated platform holds 221 bispecific/multispecific antibody projects, with 74 projects in clinical Phase I/II, 10 in Phase III, and 3 in commercialization, all representing high-potential assets. This is also one of the industry's largest and most technologically advanced bispecific/multispecific antibody development pipelines.

Smart Finance APP understands that Wuxi Bio has built a "highway" for complex molecule projects from laboratory to commercialization. Bispecific/multispecific antibody projects can be efficiently completed from DNA to IND filing within 6 months, and from technology transfer to PPQ completion in just 3.5 months, accelerating the overall timeline by more than 50% compared to the industry average. By continuously empowering global clients to advance their bispecific/multispecific antibody pipelines, the company has become the preferred partner for innovative drug companies seeking late-stage pipeline realization globally.

The ADC segment has also delivered outstanding performance. Wuxi XDC's 2026 interim results were impressive, with total comprehensive income reaching RMB 3.701 billion, up 37.0% year-over-year at actual exchange rates (AER) and 41.5% at constant exchange rates (CER), further demonstrating Wuxi Bio's dominance in the complex molecule track. This is precisely the industry spillover effect brought by its solid technical barriers, and such high-end increments will bring Wuxi Bio advantages of high customer stickiness, high margins, and high sustainability.

CICC's latest research report affirmed Wuxi Bio's innovative technology platform strength and barriers in the complex molecule track, pointing out that the company's platform capabilities are gradually upgrading from R&D efficiency tools to core competitive advantages, with the potential to continuously enhance its global competitiveness in complex molecule areas such as bispecific, multispecific antibodies, and biosimilars. The report also noted that the high difficulty of bispecific/multispecific antibody development and production, combined with high customer switching costs, leads to better project profitability and retention rates, further enhancing Wuxi Bio's revenue stickiness and commercialization flexibility.

Market Perception Reshaping and Long-Term Value Reassessment

Wuxi Bio's share price has been rising strongly, outperforming the Hang Seng Index and the pharmaceutical sector. Combined with increased attention on CXO track leaders, the market has begun to proactively revalue Wuxi Bio's commercialization transition and rising complex molecule proportion. On August 13 this year, BofA Securities published a report raising its terminal growth rate assumption for China's CRO/CDMO industry from 1% to 3% and raising target prices for multiple CXO companies. According to the report, BofA anchored on the dual data points of "financing + going global" for Chinese innovative drugs, stating that "China's medical R&D activities will further accelerate, and Chinese CRO/CDMO companies are expected to benefit." This judgment is consistent with the optimistic tone previously expressed by Nomura and Morgan Stanley regarding "Chinese innovative drug going global + supply chain repatriation," demonstrating continued signals from international banks on repricing China's CXO industry.

Among these, BofA raised its Hong Kong target price for Wuxi AppTec from HK$204.3 to HK$242, an increase of 18.4%, maintaining a "Buy" rating. Wuxi AppTec received repricing first because it has already demonstrated a complete small molecule CRDMO growth path: a massive project reserve continuously flows to the back end, with the proportion of later-stage and commercial manufacturing business rising, driving revenue scale and profit quality improvements, which in turn lifts the valuation center. As a large molecule CRDMO platform, Wuxi Bio is replicating this growth logic. The "golden funnel" of a thousand molecules not only provides a continuous source of projects but also forms a clearer value realization path through stage transitions, providing a solid fundamental basis for valuation reshaping.

Guotai Junan International, in its June research report, expressed optimism about Wuxi Bio's long-term growth space and emphasized the scarcity of the CRDMO model, giving the company an "Accumulate" rating with a target price of HK$54.49. With this interim report, Wuxi Bio has once again validated the endogenous growth power of its CRDMO platform. More and more projects are advancing along the R-D-M path, gradually entering PPQ and commercial manufacturing stages. The company's total outstanding order value grew to US$25.1 billion, with outstanding orders within three years growing to US$5.5 billion, up approximately 30% year-over-year.

It is not difficult to see that Wuxi Bio's growth logic is undergoing structural upgrades: early-stage projects continue to expand, mid-to-late-stage projects accelerate, PPQ and commercial manufacturing provide higher revenue visibility, and complex molecules further enhance project value and profit elasticity. Looking ahead, as Wuxi Bio's integrated CRDMO platform further enters a concentrated realization cycle, the commercialization results of an increasing number of molecules will serve as the core basis supporting the company's long-term value appreciation.